Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers

Obesity (Silver Spring). 2016 Nov;24(11):2278-2288. doi: 10.1002/oby.21629.


Objective: To identify an early response criterion for predicting ≥5% weight loss with liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) and early nonresponders (ENRs).

Methods: Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks. Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.

Results: Proportions of ERs/ENRs to liraglutide 3.0 mg were 77.3%/22.7% (individuals without type 2 diabetes, T2D) and 62.7%/37.3% (those with T2D). Greater mean weight loss was observed in ERs versus ENRs: 10.8% versus 3.0% (without T2D) and 8.5% versus 3.1% (T2D). In both trials, greater proportions of ERs versus ENRs achieved ≥5%, >10%, and >15% weight loss at week 56 with liraglutide 3.0 mg. Greater improvements in cardiometabolic risk factors and health-related quality of life scores were observed in ERs versus ENRs.

Conclusions: The early response criterion was clinically useful to identify individuals who would achieve clinically meaningful weight loss at 56 weeks.

Trial registration: ClinicalTrials.gov NCT01272219 NCT01272232.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anti-Obesity Agents / pharmacology*
  • Biomarkers / blood*
  • Body Mass Index
  • Body Weight
  • Cardiovascular System / drug effects
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Endpoint Determination
  • Exercise
  • Female
  • Humans
  • Liraglutide / pharmacology*
  • Male
  • Middle Aged
  • Obesity / blood
  • Prediabetic State / blood
  • Quality of Life
  • Respiratory System / drug effects
  • Risk Factors
  • Treatment Outcome
  • Weight Loss / drug effects*


  • Anti-Obesity Agents
  • Biomarkers
  • Liraglutide

Associated data

  • ClinicalTrials.gov/NCT01272219
  • ClinicalTrials.gov/NCT01272232